Company Profile | ![]() | 0-9 | ![]() | A | ![]() | B | ![]() | C | ![]() | D | ![]() | E | ![]() | F | ![]() | G | ![]() | H | ![]() | I | ![]() | J | ![]() | K | ![]() | L | ![]() | M | ![]() | N | ![]() | O | ![]() | P | ![]() | Q | ![]() | R | ![]() | S | ![]() | T | ![]() | U | ![]() | V | ![]() | W | ![]() | X | ![]() | Y | ![]() | Z |
WPP plc
(NYSE: WPP)
|
8:00 PM UTC, 04/16/25 | |||
---|---|---|---|---|
Last: $35.46 | Change: -0.97 | %Change: -2.66% | Volume: 224,463 |
11:11 AM EDT, 04/01/2025 (MT Newswires) -- European equities traded in the US as American depositary receipts were treading water late Tuesday morning, edging 0.02% higher to 1,397.86 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and telecommunications company Nokia (NOK), which were up 2.4% and 1.6% respectively. They were followed by petroleum refiner Equinor (EQNR) and financial services company Banco Santander (SAN), which increased 1.4% and 1.1% respectively.
The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which shed 10% and 8.7% respectively. They were followed by biopharmaceutical company Genfit (GNFT) and pharmaceutical company Ascendis Pharma (ASND), which lost 3.3% and 2.4% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies NuCana (NCNA) and Adaptimmune Therapeutics (ADAP), which rose 8.2% and 6.9% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Akari Therapeutics (AKTX), which advanced 5% and 3.2% respectively.
The decliners from the UK and Ireland were led by communications company WPP (WPP) and biopharmaceutical company Bicycle Therapeutics (BCYC), which dropped 5.7% and 4.2% respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and pharmaceutical company Silence Therapeutics (SLN), which were down 3.6% and 3.5% respectively.
http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.